The role of IDO in brain tumor immunotherapy

Journal of Neuro-Oncology

Volumn 123, Issue 3, 2015, Pages 395-403

  Zhai, Lijie ^a   Lauing, Kristen L ^a   Chang, Alan L ^b   Dey, Mahua ^b   Qian, Jun ^a   Cheng, Yu ^c   Lesniak, Maciej S ^b   Wainwright, Derek A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glioblastoma; IDO2; Immunosuppression; Kynurenine; TDO; Tryptophan

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; BENATOPRAZOLE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; MESSENGER RNA; NIVOLUMAB; NLG 919; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN;

AMINO ACID SYNTHESIS; APOPTOSIS; BRAIN SURGERY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; LINKAGE ANALYSIS; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TRYPTOPHAN METABOLISM; UPREGULATION; ANIMAL; BRAIN NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES;

ANIMALS; BRAIN NEOPLASMS; HUMANS; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE;

EID: 84937517015     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1687-8     Document Type: Review

References (60)

1. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
2. Curiel TJ et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949
3. Mizukami Y et al (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 122(10):2286–2293
4. Fecci PE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158–2167
5. Parsa AT et al (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84–88
6. Bloch O et al (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19(12):3165–3175
7. (2013) PD-1 inhibitor becomes “breakthrough therapy”. Cancer Discov 3(7): p. OF14
8. Mitsuka K et al (2013) Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 72(6):1031–1039. doi:10.1227/NEU.0b013e31828cf945
9. Wainwright DA et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18(22):6110–6121
10. Boyland E (1995) The estimation of tryptophan metabolites in the urine of patients with cancer of the bladder. Biochem J 60:v Annual General Meeting
11. Wolf H, Madsen PO, Price JM (1968) Studies on the metabolism of tryptophan in patients with benign prostatic hypertrophy or cancer of the prostate. J Urol 100(4):537–543
12. Rose DP (1967) Tryptophan metabolism in carcinoma of the breast. Lancet 1(7484):239–241
13. Ivanova VD (1964) Disorders of tryptophan metabolism in leukaemia. Acta Unio Int Contra Cancrum 20:1085–1086
14. Ambanelli U, Rubino A (1962) Some aspects of tryptophan–nicotinic acid chain in Hodgkin’s disease. Relative roles of tryptophan loading and vitamin supplementation on urinary excretion of metabolites. Haematol Lat 5:49–73
15. Okamoto A et al (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16):6030–6039
16. Brandacher G et al (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12(4):1144–1151
17. Munn DH et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191–1193
18. Platten M et al (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310(5749):850–855
19. Friberg M et al (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101(2):151–155
20. Uyttenhove C et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269–1274
21. Nakamura T et al (2007) Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci 98(6):874–881
22. Chung DJ et al (2009) Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114(3):555–563
23. Sharma MD et al (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Investig 117(9):2570–2582
24. Wainwright DA et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 20:5290–5301
25. Li M et al (2014) The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer 2:21
26. Murray MF (2007) The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab 8(3):197–200
27. Yuasa H et al (2007) Evolution of vertebrate indoleamine 2,3-dioxygenases. J Mol Evol 65(6):705–714
28. Metz R et al (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan. Cancer Res 67(15):7082–7087
29. Ball HJ et al (2007) Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396(1):203–213
30. Yuasa HJ et al (2009) Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp Biochem Physiol B 153(2):137–144
31. Kanai M et al (2009) Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2:8
32. Pilotte L et al (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci 109(7):2497–2502
33. Opitz CA et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197–203
34. Munn DH et al (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189(9):1363–1372
35. Praetorius-Ibba M et al (2000) Ancient adaptation of the active site of tryptophanyl-tRNA synthetase for tryptophan binding. Biochemistry 39(43):13136–13143
36. Kudo Y, Boyd CA (2001) Characterisation of l-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. J Physiol 531(Pt 2):405–416
37. Kudo Y, Boyd CA (2000) Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim Biophys Acta 1500(1):119–124
38. Alexander AM et al (2002) Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51(2):356–365
39. Munn DH et al (2005) GCN2 kinase in T Cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22(5):633–642
40. Metz R et al (2012) IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by d-1-methyl-tryptophan. Oncoimmunology 1(9):1460–1468
41. Terness P et al (2002) Inhibition of allogeneic T Cell proliferation by indoleamine 2,3-dioxygenase–expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196(4):447–457
42. Fallarino F et al (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9(10):1069–1077
43. Mezrich JD et al (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190–3198
44. Nguyen NT et al (2010) Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci 107(46):19961–19966
45. Orabona C et al (2008) SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci 105(52):20828–20833
46. Orabona C et al (2004) CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 5(11):1134–1142
47. Pallotta MT et al (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12(9):870–878
48. Cady SG, Sono M (1991) 1-Methyl-dl-tryptophan, beta-(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291(2):326–333
49. Peterson ACM, Migawa MT, Martin MJ, Hamaker LK, Czerwinski KM, Zhang W, Arend RA, Fisette PL, Okazi Y, Will JA, Brown RR, Cook JM (1994) Evaluation of functionalized tryptophan derivatives and related compounds as competitive inhibitors of indoleamine 2,3-dioxygenase. Med Chem Res 3:531–544
50. Hou DY et al (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2):792–801
51. Austin CJ et al (2010) Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2. Amino Acids 39(2):565–578
52. Qian F et al (2012) Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother 61(11):2013–2020
53. Yuasa HJ et al (2010) 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan. Comp Biochem Physiol B 157(1):10–15
54. Liu X et al (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115(17):3520–3530
55. Meininger D et al (2011) Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta 1814(12):1947–1954
56. Bakmiwewa SM et al (2012) Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2. Bioorg Med Chem Lett 22(24):7641–7646
57. Holmgaard RB et al (2013) Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210(7):1389–1402
58. Beischlag TV et al (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18(3):207–250
59. Kerdiles YM et al (2010) Foxo transcription factors control regulatory T cell development and function. Immunity 33(6):890–904
60. Chow LM et al (2011) Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19(3):305–316